Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16

Business Wire

2020-11-11

Management to host a conference call and webcast at 4:30 PM ET on that day

Novus Therapeutics, Inc. ("Novus") (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the company will report its financial results for the three and nine months ended September 30, 2020, after the market close on Monday, November 16, 2020. Management will host a corporate update conference call and webcast at 4:30 PM Eastern Time the same day.

Conference Call Details
*Monday, November 16, at 4:30 PM Eastern Time / 1:30 PM Pacific Time*
Toll Free:				877-407-3982
International:				201-493-6780
Conference ID:				13713171
Webcast:				http://public.viavid.com/index.php?id=142451

About Novus Therapeutics

Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Novus is headquartered in Irvine, California. For more information, please visit the company’s website at www.novustherapeutics.com.

Follow Novus Therapeutics on social media: @Novus_Thera and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201110006234/en/

Contacts

Media
Amanda Sellers
asellers@vergescientific.com
301-332-5574

Investors
Bruce Mackle
LifeSci Advisors. LLC
bmackle@lifesciadvisors.com
929-469-3859

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2082169064"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2082169064\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2082169064?lang=zh_TW&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GyCzyJscGV76bubIxar8.A--~B/aD0xMzI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/4diL8zQMJ1v6Cf8GJM2LsQ--~B/aD0xMzI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/42c7ae0e1b8616070f1baf520fce9712","is_english":true,"pubTime":"2020-11-11 06:04","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2082169064","market":"us","top_or_hot":-1,"title":"Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16","media":"Business Wire","content":"<html><body><p><i>Management to host a conference call and webcast at 4:30 PM ET on that day</i></p>\n<p><a href=\"https://laohu8.com/S/NVUS\">Novus Therapeutics, Inc.</a> (\"Novus\") (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the company will report its financial results for the three and nine months ended September 30, 2020, after the market close on Monday, November 16, 2020. Management will host a corporate update conference call and webcast at 4:30 PM Eastern Time the same day.</p>\n<table cellspacing=\"0\">\n<tbody>\n<tr>\n<td colspan=\"5\" rowspan=\"1\"><p><b>Conference Call Details</b></p></td>\n</tr>\n<tr>\n<td colspan=\"5\" rowspan=\"1\"><p><b><i>Monday, November 16, at 4:30 PM Eastern Time / 1:30 PM Pacific Time </i></b></p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>Toll Free:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>877-407-3982</p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>International:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>201-493-6780</p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>Conference ID:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>13713171</p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>Webcast:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>http://public.viavid.com/index.php?id=142451</p></td>\n</tr>\n</tbody>\n</table>\n<p><strong>About Novus Therapeutics </strong></p>\n<p>Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Novus is headquartered in Irvine, California. For more information, please visit the company’s website at www.novustherapeutics.com.</p>\n<p>Follow Novus Therapeutics on social media: @Novus_Thera and LinkedIn.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20201110006234/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>Media </b><br/>Amanda Sellers<br/>asellers@vergescientific.com <br/>301-332-5574</p>\n<p><b>Investors </b><br/>Bruce Mackle<br/>LifeSci Advisors. LLC<br/>bmackle@lifesciadvisors.com <br/>929-469-3859</p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Business Wire</strong><span class=\"h-time small\">2020-11-11 06:04</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p><i>Management to host a conference call and webcast at 4:30 PM ET on that day</i></p>\n<p><a href=\"https://laohu8.com/S/NVUS\">Novus Therapeutics, Inc.</a> (\"Novus\") (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the company will report its financial results for the three and nine months ended September 30, 2020, after the market close on Monday, November 16, 2020. Management will host a corporate update conference call and webcast at 4:30 PM Eastern Time the same day.</p>\n<table cellspacing=\"0\">\n<tbody>\n<tr>\n<td colspan=\"5\" rowspan=\"1\"><p><b>Conference Call Details</b></p></td>\n</tr>\n<tr>\n<td colspan=\"5\" rowspan=\"1\"><p><b><i>Monday, November 16, at 4:30 PM Eastern Time / 1:30 PM Pacific Time </i></b></p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>Toll Free:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>877-407-3982</p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>International:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>201-493-6780</p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>Conference ID:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>13713171</p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>Webcast:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>http://public.viavid.com/index.php?id=142451</p></td>\n</tr>\n</tbody>\n</table>\n<p><strong>About Novus Therapeutics </strong></p>\n<p>Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Novus is headquartered in Irvine, California. For more information, please visit the company’s website at www.novustherapeutics.com.</p>\n<p>Follow Novus Therapeutics on social media: @Novus_Thera and LinkedIn.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20201110006234/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>Media </b><br/>Amanda Sellers<br/>asellers@vergescientific.com <br/>301-332-5574</p>\n<p><b>Investors </b><br/>Bruce Mackle<br/>LifeSci Advisors. LLC<br/>bmackle@lifesciadvisors.com <br/>929-469-3859</p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/novus-therapeutics-release-third-quarter-220400084.html\">Business Wire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/novus-therapeutics-release-third-quarter-220400084.html","article_id":"2082169064","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GyCzyJscGV76bubIxar8.A--~B/aD0xMzI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/4diL8zQMJ1v6Cf8GJM2LsQ--~B/aD0xMzI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/42c7ae0e1b8616070f1baf520fce9712"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2082169064","pubTimestamp":1605045840,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Management to host a conference call and webcast at 4:30 PM ET on that day\nNovus Therapeutics, Inc. ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Novus Therapeutics将于11月16号（星期一）发布2020年第三季度财报","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVUS":0.9},"content_text":"Management to host a conference call and webcast at 4:30 PM ET on that day\nNovus Therapeutics, Inc. (\"Novus\") (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the company will report its financial results for the three and nine months ended September 30, 2020, after the market close on Monday, November 16, 2020. Management will host a corporate update conference call and webcast at 4:30 PM Eastern Time the same day.\n\n\n\nConference Call Details\n\n\nMonday, November 16, at 4:30 PM Eastern Time / 1:30 PM Pacific Time \n\n\nToll Free:\n\n\n\n877-407-3982\n\n\nInternational:\n\n\n\n201-493-6780\n\n\nConference ID:\n\n\n\n13713171\n\n\nWebcast:\n\n\n\nhttp://public.viavid.com/index.php?id=142451\n\n\n\nAbout Novus Therapeutics \nNovus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Novus is headquartered in Irvine, California. For more information, please visit the company’s website at www.novustherapeutics.com.\nFollow Novus Therapeutics on social media: @Novus_Thera and LinkedIn.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20201110006234/en/\nContacts\nMedia Amanda Sellersasellers@vergescientific.com 301-332-5574\nInvestors Bruce MackleLifeSci Advisors. LLCbmackle@lifesciadvisors.com 929-469-3859","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}